MK 1029

Drug Profile

MK 1029

Alternative Names: MK1029

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiallergics; Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • No development reported Allergic asthma

Most Recent Events

  • 01 May 2016 Phase-II clinical trials in Asthma (Adjunctive treatment) in Japan (PO) (NCT02720081)
  • 22 Mar 2016 Merck Sharp & Dohme plans a phase II trial for Asthma (Adjunctive treatment) in USA (PO) (NCT02720081)
  • 29 Dec 2015 No recent reports on development identified - Phase-I for Allergic asthma in United Kingdom (PO, capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top